Receptors for chemotactic formyl peptides as pharmacological targets

International Immunopharmacology

Volumn 2, Issue 1, 2002, Pages 1-13

  Le, Yingying ^a   Yang, Yiming ^a   Cui, Youhong ^a   Yazawa, Hiroshi ^a   Gong, Wanghua ^b   Qiu, Cunping ^a   Wang, Ji Ming ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Alzheimer's disease; Chemotaxis; Formyl peptide receptors; HIV 1; Prion diseases

Indexed keywords

AMYLOID BETA PROTEIN; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CHEMOTACTIC PEPTIDE; CHENODEOXYCHOLIC ACID; CYCLOSPORIN H; DEOXYCHOLIC ACID; DP 107; DRUG RECEPTOR; ENFUVIRTIDE; F PEPTIDE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; FORMYLPEPTIDE; FORMYLPEPTIDE RECEPTOR; G PROTEIN COUPLED RECEPTOR; LIPOCORTIN 1[1-26]; LIPOCORTIN 1[9-25]; MITOCHRONDRIAL PEPTIDE; N 36; PRION PROTEIN[106-126]; PROTEIN LXA4; PROTEIN MMK 1; SERUM AMYLOID A; T 21; UNCLASSIFIED DRUG; UNINDEXED DRUG; V3 PEPTIDE; VIRUS ENVELOPE PROTEIN; W PEPTIDE;

ALZHEIMER DISEASE; AMYLOIDOSIS; DEGENERATIVE DISEASE; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHARMACOLOGY; INFLAMMATION; LEUKOCYTE MIGRATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN SAA; PROTEIN SECRETION; RECEPTOR AFFINITY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CHEMOTACTIC FACTORS; HUMANS; LEUKOCYTES; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LIPOXIN; RECEPTORS, PEPTIDE;

EID: 0035178393     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00150-3     Document Type: Review

References (112)

1. N-formylmethionyl peptides as chemoattractants for leukocytes
2. The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli
3. Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli
4. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils
5. The N-formyl peptide chemotactic receptors
6. The N-formyl peptide receptor: A model for the study of chemoattractant receptor structure and function
7. Down-regulation of the chemokine receptor CCR5 by activation of chemotactic formyl peptide receptor in human monocytes
8. The synthetic peptide WKYMVm attenuates the function of the chemokine receptors CCR5 and CXCR4 through activation of the formyl peptide receptor-like 1
9. Activation of the chemotactic peptide receptor FPRL1 in monocytes phosphorylates the chemokine receptor CCR5 and attenuates cell responses to selected chemokines
10. Desensitization of chemokine receptor CCR5 in dendritic cells at the early stage of differentiation by activation of formyl peptide receptors
11. Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor
12. A seven-transmembrane, G-protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells
13. 42 activates a G protein-coupled chemoattractant receptor FPR-like 1
14. The neurotoxic prion peptide fragment PrP(106-126) is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1
15. Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19
16. A structural homologue of the N-formyl peptide receptor: Characterization and chromosome mapping of a peptide chemoattractant receptor family
17. Isolation of a cDNA that encodes a novel granulocyte N-formyl peptide receptor
18. Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors
19. Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding: Construction and analysis of chimeric N-formyl peptide receptors
20. Differential expression of members of the N-formylpeptide receptor gene cluster in human phagocytes
21. N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation
22. Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines
23. Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia
24. FMLP actions and its binding sites in isolated human coronary arteries
25. Broad immunocytochemical localization of the formylpeptide receptor in human organs, tissues and cells
26. Species and subtype variants of the N-formyl peptide chemotactic receptor reveal multiple important functional domains
27. Molecular evolution of the N-formyl peptide and C5a receptors in non-human primates
28. Molecular cloning of the fMet-Leu-Phe receptor from neutrophils
29. The rabbit neutrophil N-formyl peptide receptor: cDNA cloning, expression, and structure/function implications
30. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release
31. Expression of functional formyl peptide receptors by human astrocytoma cell lines
32. Phagocytic cells: Stimulus-response coupling mechanisms
33. Differences in phosphorylation of formylpeptide and C5a chemoattractant receptors correlated with differences in desensitization
34. Chemoattractant receptors activate distinct pathways for chemotaxis and secretion: Role of G-protein usage
35. Two distinct Gi-proteins mediate formyl peptide receptor signal transduction in human leukemia (HL-60) cells
36. Differential activation of dibutyryl cAMP-differentiated HL-60 human leukemia cells by chemoattractants
37. Quantitative analysis of formyl peptide receptor coupling to Gi α 1, Gi α 2, and Gi α 3
38. Isozyme-selective stimulation of phospholipase C-β2 by G Protein βγ-subunits
39. Gbetagamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit
40. fMet-Leu-Phe stimulates proinflammatory cytokine gene expression in human peripheral blood monocytes: The role of phosphatidylinositol 3-kinase
41. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration
42. Roles of PLC-β2 and-β3 and PI3Kγ in chemoattractant-mediated signal transduction
43. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation
44. Stimulation of human neutrophils with fMLP induces tyrosine phosphorylation and activation of two distinct mitogen-activated protein kinase
45. Formyl peptide receptors are coupled to multiple mitogen-activated protein kinase cascades by distinct signal transduction pathways: Role in activation of reduced nicotinamide adenine dinucleotide oxidase
46. G protein-coupled chemoattractant receptors regulate lyn tyrosine kinase-Shc adapter protein signaling complexes
47. Agonist-dependent phosphorylation of N-formylpeptide and activation peptide from the fifth component of C (C5a) chemoattractant receptors in differentiated HL60 cells
48. Desensitization of N-formylpeptide receptor-mediated activation is dependent upon receptor phosphorylation
49. Phosphorylation of the N-formyl peptide receptor is required for receptor internalization but not chemotaxis
50. Arrestin binding to the G protein-coupled N-formyl peptide receptor is regulated by the conserved "DRY" sequence
51. Differential coupling of the formyl peptide receptor to adenylate cyclase and phospholipase C by the pertussis toxin-insensitive Gz protein
52. High constitutive activity of the human formyl peptide receptor
53. A peptide with unique receptor specificity: Stimulation of phosphoinositide hydrolysis and induction of superoxide generation in human neutrophils
54. Trp-Lys-Tyr-Met-Val-D-Met stimulates superoxide generation and killing of Staphylococcus aureus via phospholipase D activation in human monocytes
55. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation
56. Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast
57. Synthetic peptide MMK-1 is a highly specific chemotactic agonist for leukocyte FPRL1
58. T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor
59. The HIV-1 cell entry inhibitor T-20 potently chemoattracts neutrophils by specifically activating the N-formylpeptide receptor
60. T21/DP107, a synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G protein-coupled formyl peptide receptors
61. N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes
62. A synthetic peptide derived from HIV-1 gp120 down-regulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the seven-transmembrane G protein-coupled receptor FPRL1/LXA4R
63. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells
64. The acute-phase response
65. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins
66. Microglia and Alzheimer's disease
67. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment
68. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor
69. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors
70. Activation of lipoxin A4 receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation
71. A novel ligand of the formyl peptide receptor: Annexin I regulates neutrophil extravasation by interacting with the FPR
72. Further studies on the structural requirements for synthetic peptide chemoattractants
73. Formylpeptide receptor antagonists: Structure and activity
74. N-terminus urea-substituted chemotactic peptides: New potent agonists and antagonists toward the neutrophil fMLF receptor
75. Selective inhibition of N-formylpeptide-induced neutrophil activation by carbamate-modified peptide analogues
76. Differential inhibition of human neutrophil activation by cyclosporins A, D, and H: Cyclosporin H is a potent and effective inhibitor of formyl peptide-induced superoxide formation
77. Cyclosporin H is a potent and selective formyl peptide receptor antagonist: Comparison with N-t-Butoxycarbonyl-L-phneylalanyl-L-leucyl-L-phenylalanyl-L-leucyl-L- phenylalanine and Cyclosporins A, B, C, D, and E
78. Cyclosporin H is a potent and selective competitive antagonist of human basophil activation by N-formyl-methionyl-leucyl-phenylalanine
79. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors
80. HIV-1 gp41 is a potent inhibitor of chemoattractant receptor expression and function in monocytes
81. HIV-1 envelope gp120 inhibits monocyte response to chemokines through CD4 signal-dependent chemokine receptor down-regulation
82. Neutralization of HIV-1: A paradox of humoral proportions
83. Decline of anti-DP107 antibody associated with clinical progression
84. Chemoattractant receptor cross-desensitization
85. Amyloid deposits and amyloidsis
86. Amyloidosis: A final common pathway for protein deposition in tissues
87. Translating cell biology into therapeutic advances in Alzheimer's disease
88. Inflammation as a pathogenic mechanism in Alzheimer's disease
89. Inflammation and Alzheimer's disease
90. PKC and tyrosine kinase involvement in amyloid beta (25-35)-induced chemotaxis of microglia
91. Alzheimer's beta-amyloid peptide 1-42 induces a phagocytic response in murine microglia
92. Activation of nuclear factor-kappa B by beta-amyloid peptides and interferon-gamma in murine microglia
93. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia
94. Antiinflammatory drugs and Alzheimer's disease
95. Risk of Alzheimer's disease and duration of NSAID use
96. Clinical trial of indomethacin in Alzheimer's disease
97. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease
98. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging
99. Suppression of A beta-induced monocyte neurotoxicity by antiinflammatory compounds
100. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease
101. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils
102. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease
103. Beta-amyloid-induced IL-1 beta release from an activated human monocyte cell line is calcium- and G-protein-dependent
104. Chemotactic-like receptors and Abeta peptide induced responses in Alzheimer's disease
105. Prions
106. The contribution of inflammation to acute and chronic neurodegeneration
107. Microglia and prion disease: A review
108. Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines
109. Activation of microglial cells by PrP and beta-amyloid fragments raises intracellular calcium through L-type voltage sensitive calcium channels
110. 2+ in microglia activated by prion protein fragment
111. Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins
112. Early-onset familial Alzheimer disease with coexisting β-amyloid and prion pathology